医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Poxel and Sumitomo Dainippon Pharma Announce Initiation of Phase 3 Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan

2017年12月27日 PM04:00
このエントリーをはてなブックマークに追加


 

LYON, France & OSAKA, Japan

POXEL SA (Euronext – POXEL – FR0012432516, hereinafter called “Poxel”), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes, and Sumitomo Dainippon Pharma Co., Ltd (Head Office: Osaka, Japan; Representative Director, President and CEO: Masayo Tada; Securities Code: 4506, First Section of TSE, hereinafter called “Sumitomo Dainippon Pharma”), announced today the initiation of the Phase 3 program for Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan. Referred to as TIMES (Trials of IMeglimin for Efficacy and Safety), the Imeglimin Phase 3 program in Japan will include three pivotal trials to evaluate Imeglimin’s efficacy and safety in approximately 1,100 patients. In December 2017, the first patient was included in the TIMES 1 trial, a multicenter, double-blind, placebo-controlled, randomized, monotherapy study in over 200 Japanese patients with type 2 diabetes.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171226005233/en/

The TIMES program is a joint development effort between Poxel and Sumitomo Dainippon Pharma. The companies announced on October 30, 2017, a strategic partnership for the development and commercialization of Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries.*

“Initiation of the TIMES program is a major milestone for Poxel and for the development of Imeglimin with our partner Sumitomo Dainippon Pharma. Based on the success of our Phase 2 program, we have a clear roadmap for the Phase 3 TIMES program,” said Thomas Kuhn, CEO of Poxel. “Our near-term focus in Japan is the successful execution of TIMES, and, to this end, we will work closely with our colleagues at Sumitomo Dainippon Pharma to support the Japanese New Drug Application submission.”

“Our commitment to diabetes patients is to continue to innovate and provide the best medicines to help them manage their disease. We are pleased to be working closely with Poxel and initiating the TIMES registration studies,” said Nobuyuki Hara, Director, Executive Officer; Drug Development Division of Sumitomo Dainippon Pharma. “Diabetes is a significant area for us in Japan and we believe that Imeglimin will be a very important addition to our existing diabetes franchise.”

Imeglimin is an orally-available drug candidate with a novel mechanism of action, that has been observed in clinical studies to demonstrate glucose lowering benefits by simultaneously targeting all three key organs which play an important role in the treatment of type 2 diabetes: the liver, muscles and the pancreas. Imeglimin has demonstrated in preclinical studies the potential to address mitochondrial dysfunction, which is believed to be at the core of type 2 diabetes pathophysiology. Imeglimin has completed Phase 1 and Phase 2 development in over 1,200 subjects in the U.S., EU and Japan.

About the TIMES Program

TIMES (Trials of Imeglimin for Efficacy and Safety), the Phase 3 program for Imeglimin for the treatment of type 2 diabetes in Japan, will consist of three pivotal trials involving approximately 1,100 patients. The TIMES program will include the following three trials that will be performed using the dose of 1,000 mg twice daily:

TIMES 1: A Phase 3, 24-week, double-blind placebo-controlled, randomized, monotherapy study to assess the efficacy, safety and tolerability of Imeglimin in Japanese patients with type 2 diabetes, using the change in HbA1c as the primary endpoint. Secondary endpoints of the trial will include other standard glycemic and non-glycemic parameters.

TIMES 2: A Phase 3, 52-week, open-label, parallel-group study to assess the long-term safety and efficacy of Imeglimin in Japanese patients with type 2 diabetes. In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor, biguanide, sulphonylurea and GLP1 receptor agonist.

TIMES 3: A Phase 3, 16-week, double-blind, placebo-controlled, randomized study with a 36-week open-label extension period to evaluate the efficacy and safety of Imeglimin in combination with insulin in Japanese patients with type 2 diabetes and inadequate glycemic control on insulin therapy.

About Imeglimin

Imeglimin is the first clinical candidate in a new chemical class of oral agents called Glimins by the World Health Organization. Imeglimin has a unique mechanism of action (“MOA”) that targets mitochondrial bioenergetics. Imeglimin acts on all three key organs which play an important role in the treatment of type 2 diabetes: the liver, muscles and the pancreas, and it has demonstrated glucose lowering benefits by increasing insulin secretion in response to glucose, improving insulin sensitivity and suppressing gluconeogenesis. This MOA has the potential to prevent endothelial and diastolic dysfunction, which can provide protective effects on micro- and macro-vascular defects induced by diabetes. It also has the potential for protective effect on beta-cell survival and function. This unique MOA offers the potential opportunity for Imeglimin to be a candidate for the treatment of type 2 diabetes in almost all stages of the current anti-diabetic treatment paradigm, including monotherapy or as an add-on to other glucose lowering therapies.

About Poxel SA

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of metabolic disorders, including type 2 diabetes. We have successfully completed our Phase 2 clinical program for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S., EU and Japan, and have initiated the Phase 3 TIMES program in Japan. Our second program, PXL770, a direct AMPK activator, is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxelpharma.com)

About Sumitomo Dainippon Pharma

Sumitomo Dainippon Pharma defines its corporate mission as “to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide”. By pouring all our efforts into the research and development of new drugs, we aim to provide innovative and effective pharmaceutical solutions to people not only in Japan but also around the world in order to realize our corporate mission. Sumitomo Dainippon Pharma aims to create innovative pharmaceutical products in the Psychiatry & Neurology area and the Oncology area, which have been designated as the focus therapeutic areas. Sumitomo Dainippon Pharma has also positioned Psychiatry & Neurology, Diabetes/Cardiovascular and Speciality areas as our focus marketing areas in Japan. For more detail, please visit our website. (URL:http://www.ds-pharma.com)

*including: Indonesia, Vietnam, Thailand, Malaysia, The Philippines, Singapore, Republic of the Union of Myanmar, Kingdom of Cambodia, and Lao People’s Democratic Republic.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171226005233/en/

CONTACT

Poxel SA
Jonae R. Barnes, +1 617-818-2985
Senior
Vice President, Investor Relations and Public Relations
jonae.barnes@poxelpharma.com
or
Investor
relations / Media – EU/US

Trophic Communications
Gretchen
Schweitzer or Stephanie May,
+49 89 238 877 34 or +49 171 185 56 82
may@trophic.eu
or
Investor
relations / Media – France

NewCap
Florent Alba/Nicolas
Merigeau, +33 1 44 71 98 55
poxel@newcap.fr
or
Public
relations / Media – Japan/Asia

Cosmo PR
Tomomi
Nagasawa/Maryssa Miller, +81 3 5561 2915
poxel@cosmopr.co.jp
or
Sumitomo
Dainippon Pharma Co., Ltd.

Public Relations/Investor Relations
TEL:
+81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc